Does early antiretroviral treatment prevent liver fibrosis in HIV/HCV-coinfected patients?

Journal of Acquired Immune Deficiency Syndromes

Volumn 50, Issue 2, 2009, Pages 234-236

  Bani Sadr, Firouzé ^a   Bedossa, Pierre ^b   Rosenthal, Eric ^c   Merrien, Dominique ^d   Perre, Philippe ^e   Lascoux Combe, Caroline ^f   Cacoub, Patrice ^a   Perronne, Christian ^g   Pol, Stanislas ^a  

^a Department of Pharmacologie   (France)

^b Groupe Hospitalier Universitaire Nord   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^d Centre Hospitalier Compiegne   (France)

^e Centre Hospitalier de la Roche sur Yon   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g RAYMOND POINCARÉ HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; STAVUDINE;

ADULT; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN TISSUE; LETTER; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; SCORING SYSTEM; STEATOSIS; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECT; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIDDLE AGED; VIROLOGY;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED;

EID: 60749107258     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31818ce821     Document Type: Letter

References (13)

1. Salmon-Ceron D, Lewden C, Morlat P, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol. 2005;42:799-805.
2. Brau N. Update on chronic hepatitis C in HIV/HCV-coinfected patients: viral interactions and therapy. AIDS. 2003;17:2279-2290.
3. Shafran SD. Early initiation of antiretroviral therapy: the current best way to reduce liver-related deaths in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr. 2007;44:551-556.
4. Martin-Carbonero L, Benhamou Y, Puoti M, et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis. 2004;38:128-133.
5. Macias J, Mira JA, Lopez-Cortes LF, et al. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C. Antivir Ther. 2006;11:839-846.
6. Tural C, Fuster D, Tor J, et al. Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients. J Viral Hepat. 2003;10:118-125.
7. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated Interferon alfa-2b versus standard interferon alfa-2b, plus ribavirin for chronic hepatitis C in HIV-infected patients, randomized controlled trial. JAMA. 2004;292:2839-2848.
8. Verma S, Wang CH, Govindarajan S, et al. Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients? Clin Infect Dis. 2006;42:262-270.
9. Marine-Barjoan E, Saint-Paul MC, Pradier C, et al. Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients. AIDS. 2004;18:2163-2170.
10. Kuntzen T, Tural C, Li B, et al. Intrahepatic mRNA expression in hepatitis C virus and HIV/hepatitis C virus co-infection: infiltrating cells, cytokines, and influence of HAART. AIDS. 2008;22:203-210.
11. Brau N, Salvatore M, Rios-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol. 2006;44:47-55.
12. Macias J, Castellano V, Merchante N, et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS, 2004;18:767-774.
13. Bani-Sadr F, Carrat F, Bedossa P, et al. Hepatic steatosis in HPV-HCV coinfected patients: analysis of risk factors. AIDS. 2006;20:525-531.